Docetaxel and gemcitabine combination, as first-line treatment, in patients with extensive disease small-cell lung cancer. A phase II study of the Hellenic Cooperative Oncology Group

Απλή σελίδα τεκμηρίου
dc.contributor.authorSkarlos, D. V.en
dc.contributor.authorDimopoulos, A. M.en
dc.contributor.authorKosmidis, P.en
dc.contributor.authorPapakostas, P.en
dc.contributor.authorPavlidis, N.en
dc.contributor.authorBacoyiannis, C.en
dc.contributor.authorKiamouris, C.en
dc.contributor.authorKlouvas, G.en
dc.contributor.authorGogas, H.en
dc.contributor.authorFountzilas, G.en
dc.contributor.authorSamantas, E.en
dc.date.accessioned2015-11-24T19:23:55Z
dc.date.available2015-11-24T19:23:55Z
dc.identifier.issn0169-5002-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/22384
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntimetabolites, Antineoplastic/adverse effects/therapeutic useen
dc.subjectAntineoplastic Agents, Phytogenic/adverse effects/therapeutic useen
dc.subjectAntineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic useen
dc.subjectCarcinoma, Small Cell/*drug therapyen
dc.subjectDeoxycytidine/administration & dosage/adverse effects/*analogs &en
dc.subjectderivatives/*therapeutic useen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectLung Neoplasms/*drug therapyen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectTaxoids/administration & dosage/adverse effects/*therapeutic useen
dc.subjectTreatment Outcomeen
dc.titleDocetaxel and gemcitabine combination, as first-line treatment, in patients with extensive disease small-cell lung cancer. A phase II study of the Hellenic Cooperative Oncology Groupen
heal.abstractThere is some evidence that taxanes and gemcitabine are effective antitumor agents against small-cell lung cancer (SCLC). A total of 20 chemotherapy-naive patients with extensive disease (ED) SCLC, were treated as a part of the first step of a phase II study, with docetaxel 50 mg/m(2) and gemcitabine 1000 mg/m(2), both administered on day 1 and 8 every 3 weeks up to a total of six cycles. For patients who progressed after the first cycle or had stable disease after the second cycle of chemotherapy, protocol treatment was stopped and further treatment with the standard cisplatin or carboplatin-etoposide combination was administered. Patients were in the vast majority male smokers with a good performance status. A total of 72 cycles was delivered while patients managed to receive the 78 and 84% of the planned dose of docetaxel and gemcitabine, respectively. Only six patients responded partially and the trial ended prematurely since at least seven responses were required among the first 19 patients. With a median follow-up of 13 months, median time to progression (TTP) was 8 months and median survival 9.6 months. Hematological and non-hematological toxicity was generally acceptable while patients tolerated their treatment reasonably well. In conclusion, docetaxel-gemcitabine showed a modest response rate in chemotherapy-naive patients with ED SCLC.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/12826319-
heal.identifier.secondaryhttp://ac.els-cdn.com/S0169500203001545/1-s2.0-S0169500203001545-main.pdf?_tid=dbe5efcafe991384c9c5d31d0c9df963&acdnat=1333614043_ac24223447da3315e81b892ab58472cd-
heal.journalNameLung Canceren
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2003-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ